Roland Barge

Roland Barge

Auto-generated profile, based on publicly available information

Roland Barge

Regeneron Pharmaceuticals, Inc. Tarrytown New York USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2025 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
JBJessie P. Bakker
Jessie P. Bakker
RBRoland Barge
Roland Barge
JCJacob Centra
Jacob Centra
BCBryan Cobb
Bryan Cobb
CCChas Cota
Chas Cota
JGJennifer C. Goldsack
Jennifer C. Goldsack
We propose the addition of usability validation to the extended V3 framework, now “V3+”, and describe a pragmatic approach to ensuring that sensor-based digital health technologies can be used optimally at scale by diverse users. Alongside the original V3 components (verification; analytical validation; clinical validation), usability validation will ensure user-centricity of digital measurement tools, paving the way for more inclusive, reliable, and trustworthy digital measures within clinical research and clinical care.

3 March 2025 in Mayo Clinic Proceedings: Digital Health
Verified
Journal Article
Open access
RBRoland Barge
Roland Barge
PFPatrick Floody
Patrick Floody
To define potential participant and site perceptions of decentralized clinical trials (DCTs). Two qualitative surveys were conducted between January 2022 and August 2022 to assess current awareness of, and perceptions about, DCTs. The first survey received 141 responses from staff at our clinical trial sites; the second survey received 481 responses from US-based healthy individuals or those living with an illness. There was a difference in perceptions and willingness between participants and sites toward DCTs. Participants expressed more comfort with hybrid and fully remote trials than did the sites. Site staff were more concerned and less trusting than participants of DCTs; participants’ main concerns were regarding practicality and medical safety, whereas the focus for sites was on burden, trust, and security. Both sites and participants expressed confidence in fully remote clinical study activities when they have appropriate support; sites were less tolerant of fully remote clinical study activities if professional support was not provided. Overall, sites were more willing to manage the use of DCT-related technologies than were participants. It is highly likely that participants’ willingness to manage DCT technologies relates to the perceived burden of use (ie, willingness decreases as burden or impact on daily life increases). Sponsors, contract research organizations, and DCT vendors generally had positive views on DCTs. However, different stakeholders had different concerns. These results highlight the need for collaborative research and development of DCTs, as well as a clear DCT framework and regulatory guidance.

24 February 2026 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
DHDeborah A. Hall
Deborah A. Hall
KKKimberly Kwei
Kimberly Kwei
RARolando J. Acosta
Rolando J. Acosta
BKBharatkumar Koyani
Bharatkumar Koyani
ERErin Robertson
Erin Robertson
JOJoan A. O'KEefe
Joan A. O'KEefe
Objective: Gait impairment is a distinctive symptom of Parkinson's disease that negatively impact mobility. We assessed the validity of wearable digital insoles against a validated reference gait analysis system for measuring select gait characteristics in patients with Parkinson's disease. Methods: A comparative analysis between digital insoles (Moticon ReGo Insole) and the GAITRite system was conducted in patients with Parkinson's disease. Patients were assessed in both the OFF and ON medication states. Gait characteristics were measured simultaneously with both systems during two 10 m walk tests. Patients also completed a patient experience survey following the use of the digital insoles. Results: Overall, 21 patients with Parkinson's disease were included in the study. Analytical validation for gait cadence, speed, and stride length showed excellent agreement (intraclass correlation coefficients between 0.93–0.97) in both the OFF and ON states. Stance, swing, and double support times exhibited lower validity with moderate agreement (intraclass correlation coefficients from 0.48–0.57). Gait speed and stride length were significantly associated with scores on the Movement Disorders Society's Unified Parkinson's Disease Rating Scale ( p = 0.0085 and 0.013, respectively). Mean differences in all parameters measured with the insoles, except cadence, were significantly different between OFF and ON states ( p < 0.003). The majority of patients liked wearing the digital insoles and found them comfortable and user‐friendly. Interpretation: These findings support the validity of Moticon ReGo digital insoles for the assessment of several important gait characteristics in Parkinson's disease.